Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

INTRODUCTION: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. We evaluated its efficacy versus imatinib-based regimens using a matching...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribera, Josep-Maria, Prawitz, Thibaud, Freitag, Andreas, Sharma, Anuj, Dobi, Balázs, Rizzo, Federica, Sabatelli, Lorenzo, Patos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272268/
https://www.ncbi.nlm.nih.gov/pubmed/37208556
http://dx.doi.org/10.1007/s12325-023-02497-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272268/
https://www.ncbi.nlm.nih.gov/pubmed/37208556
http://dx.doi.org/10.1007/s12325-023-02497-y

Ejemplares similares